“As Big Pharma downsizes, a major loss of brain power."
The above Philadelphia Inquirer article follows several women in the pharmaceutical industry who have been laid off in the past months. The women are part of a trend that has seen thousands of pharmaceutical researchers, developers, marketers, and other employees losing jobs. The reason for the down-size is that many so-called “blockbuster drugs”-- high-earning drugs that treat common problems-- are now coming off their patents, meaning that any company (not just Merck or Pfizer) can develop generic versions of these drugs for cheaper. This equates to a substantial loss of revenue for the big players in the industry, who had gleaned most of their profit from these drugs. It also means big changes for industry-led research, which will now likely focus on developing so-called “niche” drugs that treat less common conditions.
While the content is informative, I find the tone and scope of this piece deeply unsettling.